ADVM icon

Adverum Biotechnologies

2.21 USD
-0.50
18.45%
At close May 13, 4:00 PM EDT
Pre-market
2.29
+0.08
3.62%
1 day
-18.45%
5 days
-32.62%
1 month
-35.57%
3 months
-48.48%
6 months
-70.77%
Year to date
-53.96%
1 year
-75.90%
5 years
-98.73%
10 years
-99.38%
 

About: Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Employees: 155

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]

5.13% less ownership

Funds ownership: 81.45% [Q3] → 76.32% (-5.13%) [Q4]

9% less funds holding

Funds holding: 76 [Q3] → 69 (-7) [Q4]

27% less call options, than puts

Call options by funds: $45K | Put options by funds: $62K

38% less capital invested

Capital invested by funds: $120M [Q3] → $74.1M (-$46M) [Q4]

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
126%
upside
Avg. target
$23
926%
upside
High target
$33
1,393%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Chardan Capital
Daniil Gataulin
23% 1-year accuracy
13 / 57 met price target
1,393%upside
$33
Buy
Maintained
17 Apr 2025
RBC Capital
Luca Issi
13% 1-year accuracy
7 / 54 met price target
126%upside
$5
Sector Perform
Maintained
16 Apr 2025
HC Wainwright & Co.
Matthew Caufield
30% 1-year accuracy
20 / 66 met price target
1,257%upside
$30
Buy
Reiterated
16 Apr 2025

Financial journalist opinion

Based on 38 articles about ADVM published over the past 30 days

Neutral
Accesswire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
6 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
PRNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
GlobeNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
GlobeNewsWire
1 week ago
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4).
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Charts implemented using Lightweight Charts™